Important cutaneous manifestations of inflammatory bowel disease

L B Trost, J K McDonnell

Inflammatory bowel disease (IBD) has many extraintestinal manifestations. Cutaneous manifestations are usually related to the activity of the bowel disease but may have an independent course. Anyone presenting with IBD should be examined for cutaneous manifestations. Pyoderma gangrenosum is a severe painful ulcerating disease that requires moist wound management and, in the absence of secondary infection, systemic corticosteroids, cyclosporine, or both. Infliximab may also be used. Erythema nodosum is a common cause of tender red nodules of the shins. Management includes leg elevation, NSAIDs, and potassium iodide. Oral manifestations of IBD include aphthous stomatitis, mucosal nodularity (cobblestoning), and pyostomatitis vegetans. Treatment should be directed both at the cutaneous lesions and at the underlying systemic condition.

Inflammatory bowel disease (IBD) is a common clinical entity that affects 0.37% of the population. Its two main subtypes, Crohn’s disease (CD) and ulcerative colitis (UC), are commonly associated with abdominal pain, diarrhoea, rectal bleeding, weight loss, and signs of malnutrition. IBD is associated with a wide array of extraintestinal manifestations, including cutaneous, musculoskeletal, hepatobiliary, ocular, and metabolic conditions (see box 1). One third of patients with IBD will develop an extraintestinal manifestation. Of those patients, up to one third will develop cutaneous manifestations.

Patients presenting with IBD should be examined thoroughly for cutaneous manifestations. This article will discuss the epidemiology, pathophysiology, diagnosis, and management of important cutaneous manifestations of IBD.

PYODERMA GANGRENOSUM
Epidemiology and pathophysiology

Pyoderma gangrenosum (PG) is a severe ulcerating non-infectious neutrophilic dermatosis. UC is the most common underlying disease associated with PG in adults. PG has been reported in 1% to 10% of patients with UC and in 0.5% to 20% of patients with CD. It occurs equally in men and women with a peak age incidence between 25 and 54 years. Some 50%–78% of patients with PG have an underlying systemic disease such as IBD, myeloproliferative disease, and rheumatological disease. While the pathophysiology is not completely understood, it is thought to involve impaired cellular immunity and abnormal neutrophil function.

Presentation

Four variants of PG have been described: ulcerative, pustular, bullous, and vegetative. Ulcerative and pustular PG are associated with IBD, arthritis, and malignancy, whereas bullous PG is associated with myeloproliferative disorders. Vegetative PG usually has no associated underlying systemic conditions. PG can occur before, during, or after the onset of IBD, and both diseases can occur independently of one another. Classically, PG begins with pain, followed by pustule formation and rapid ulceration. A sterile, purulent necrotic centre remains and is surrounded by a bluish border. It most commonly occurs on the lower extremities although it can occur on any part of the body (see fig 1). About half of patients with PG develop large ulcers in response to minor trauma (for example, venipuncture and surgical debridement).

Diagnosis

PG is a diagnosis of exclusion. Box 2 lists the differential diagnosis of PG. It is vital to exclude infectious aetiologies because infection may preclude the use of systemic corticosteroids and other immunosuppressants. Underlying systemic diseases must be identified and treated.

A detailed history should address exposure to sulphur, ingestion of iodide or bromide, and recent spider bites. Routine testing for bacteria, mycobacteria, and deep fungal infection from tissue cultures is recommended. Additional studies may include sulphis zarate (antiphospholipid antibody levels, serum protein electrophoresis, immunoepitopelectrophoresis, and serum iodide and bromide levels. Tissue should be examined histologically to rule out other diseases. Currently, specific laboratory or histopathological tests for PG are not available. In classic ulcerative PG, there is neutrophilic infiltrate centrally in the ulcer and lymphocytic infiltrate in the periphery.

Management

Management should be directed at both the lesions of PG and at the underlying disorder. To date, almost all reports of efficacy have come from case series and case reports rather than randomised prospective controlled trials.

Abbreviations: IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; PG, pyoderma gangrenosum; EN, erythema nodosum
Lesion specific management can include topical, intraleisonal, and systemic therapies. Moist wound management with an emphasis on preventing secondary infections is crucial. Hydroactive dressings, foam dressings, and laminate dressings are commonly used. Hydrogen peroxide is not recommended because of wound cell toxicity. Topical sodium cromoglycate has been reported to be effective with and without systemic corticosteroid therapy. Topical corticosteroid therapy has been successful in treating peristomal PG, while in non-peristomal skin, local injections of triamcinolone acetonide 10–40 mg/ml with and without systemic corticosteroids have been used. If secondary infection occurs, topical and intraleisonal corticosteroid therapy is contraindicated.

Prednisone is generally considered the drug of choice. Initial doses range from 1 to 2 mg/kg/day. Cyclosporine at doses ranging from 3 to 5 mg/kg/day has been shown to be effective in case reports both alone and in combination with systemic corticosteroids and should be considered in refractory cases of PG. Sulfa drugs (for example, sulfasalazine, sulfapyridine, and sulfamethoxypyridazine) are also commonly used. Pulse methylprednisolone treatment has had mixed results in various reports. Other systemic agents that have either limited or conflicting results include dapsone, clofazimine, minocycline, azathioprine, alkylating agents, FK506 (tacrolimus), and cyclophosphamide. A recent retrospective review of 86 patients with PG showed that the average length of treatment with systemic agents was 11.5 months, and although most lesions healed within one year, 95% had remitted in three years.

In the past few years infliximab, a chimeric anti-TNFα monoclonal antibody, has shown great promise in treating refractory PG associated with CD. Infliximab is currently approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis and CD, but its efficacy has been reported in a wide range of inflammatory conditions. In the treatment of refractory PG associated with CD, favourable responses have been reported to occur within 12 hours to one week, with complete healing occurring in 1 to 11 weeks. In most reports, infliximab was given at a dose of 5 mg/kg, and treatments were spaced out
several weeks apart. However, some cases showed only temporary improvement or no improvement at all. Although surgery can cause exacerbations of PG, cutaneous surgery has been shown to be effective at inducing disease remission, but it must be performed in conjunction with immunosuppressive therapies in patients with remitting or stable disease. Options include split-skin grafts and autologous keratinocyte grafts. Because the course of PG can be independent of the course of IBD and has even been reported years after proctocolectomy, bowel resection is not a primary therapy.

**ERYTHEMA NODOSUM**

**Epidemiology and pathophysiology**

Erythema nodosum (EN) is the most common cause of lower extremity inflammatory nodules and has been associated with IBD in 11% of cases, occurring more frequently in patients with UC than CD. It occurs in women three to six times more frequently than in men and has a peak age incidence between 20 and 30 years. EN is most commonly associated with streptococcal infections, medications, sarcoidosis, autoimmune disorders, and IBD (see box 3). The precise aetiology is thought to be a hypersensitivity response involving immune complex deposition in and adjacent to vessels in the septa of connective tissue in subcutaneous fat.

**Presentation**

EN is characterised by the sudden onset of multiple, bilateral, symmetric, red, warm, and painful nodules about 2 cm in diameter. These lesions most commonly occur on the shins but may also occur on the calves, trunk, and face (see fig 2). Systemic symptoms such as fever, malaise, and joint pain often occur. The typical course lasts for three to six weeks, but the residual bruise-like lesions can last for months. Neither ulceration nor scarring occurs in EN. In patients with IBD, eruptions of EN often are associated with exacerbations of the bowel disease but not with the severity or extent.

**Diagnosis**

A search for an associated disease should always accompany the diagnosis of EN. Although an extensive examination is not needed, both common and serious underlying conditions should be considered. A complete history should include the duration of symptoms and previous similar episodes, history of drug intake (especially oral contraceptives), pregnancy, diarrhoea, and recent pharyngitis, tonsillitis, or upper respiratory tract infection (URI) in the past three weeks. Physical examination findings of arthritis or periarticular ankle inflammation may be indicative of acute sarcoidosis. Also, lymphadenopathy is often found in malignancies such as non-Hodgkin’s lymphoma. Tuberculosis and coccidioidomycosis should be considered in high risk groups.

Laboratory tests should be used depending on the degree of clinical suspicion. Reasonable initial tests include complete blood count (white blood cells with a high percentage of neutrophils and bands often occur), ACE level, ASO titre, and chest radiography. A tuberculin skin test and blood samples for bacterial, virological, fungal, and protozoal infections that are endemic to the area may also be appropriate. If a biopsy is taken, it should be excisional so that the subcutaneous adipose tissue is included in the specimen.
In most cases, EN is self-limiting and will resolve in three to six weeks without scar formation. However, late stage bruising, arthralgias, and joint stiffness may last for months. Recurrences are rare.37 38 43 When associated with IBD, EN usually will resolve with control of the IBD and often will recur with exacerbations of the bowel disease.37 In a study of 792 patients with IBD, every case of EN (48 patients) responded to medical treatment of the IBD.21

Management should be both supportive and directed at the underlying associated condition. Supportive treatment includes leg elevation, support stockings, and bed rest. 44 Aspirin and NSAIDs may also help with pain control and healing. Naproxen45 and indomethacin 46 47 have been reported to be effective in cases refractory to aspirin and NSAID therapy. In addition, potassium iodide has been reported to be successful.42 Other less common systemic treatments include colchicine and hydroxychloroquine.38

**Key references**

healing and reduce pain. Systemic corticosteroids should only be used in refractory cases or in persistent or severe aphthae.54

MUCOSAL NODULARITY (COBBLESTONING)
Mucosal nodularity, known as cobblestoning, appears as mucosal coloured papules forming firm plaques on the buccal mucosa and palate. Lesions, although infrequent, are specific for CD. Cobblestoning may be painful and interfere with speaking and eating.29–37 Treatment of the underlying disease is necessary. In addition, systemic corticosteroids are effective, although topical corticosteroids can be used in less severe cases.68

PYOSTOMATITIS VEGETANS
Pyostomatitis vegetans is a rare oral ulcerative disorder seen in patients with UC and less frequently CD. Pustules, erosions, and vegetative plaques appear on the buccal and gingival mucosa and form a “snail track” appearance. Pyostomatitis vegetans is a specific marker for IBD.39–43 Generally, IBD precedes the onset of pyostomatitis vegetans and mimics the activity of the bowel disease,44 although it has been reported with asymptomatic UC.45 Treating the underlying condition is essential and may cause resolution of the oral lesions.46 Topical corticosteroids have been useful in some cases, but the treatment of choice is systemic corticosteroids. Some have used systemic corticosteroids with dapsone or azathioprine,47 while one recent case report had success with cyclosporine A.48

CONCLUSION
Cutaneous manifestations of inflammatory bowel disease are common. Patients presenting with IBD should be examined for cutaneous manifestations. Treatment should be directed both at the cutaneous lesions and at the underlying systemic condition.

MULTIPLE CHOICE QUESTIONS (ANSWERS AT THE END OF THE REFERENCES)

1. Which disease is associated with lesions that occur in response to minor trauma?
   (A) Pyoderma gangrenosum
   (B) Aphthous stomatitis
   (C) Pyostomatitis vegetans

2. When treating pyoderma gangrenosum, which is generally considered the drug of choice?
   (A) Debridement
   (B) Potassium iodide
   (C) Prednisone
   (D) Alefacept

3. On which part of the body do the lesions of erythema nodosum classically occur?
   (A) Trunk
   (B) Hands
   (C) Face
   (D) Shins

4. Which is not a treatment for erythema nodosum?
   (A) Leg elevation
   (B) NSAIDs
   (C) Potassium iodide
   (D) Infliximab

5. What is one way that aphthous stomatitis may be distinguished from Behcet’s disease?
   (A) Aphthous stomatitis is associated with uveitis, iritis, and genital ulcers
   (B) Behcet’s disease is associated with uveitis, iritis, and genital ulcers
   (C) Aphthous stomatitis is associated with ulcers on the shins
   (D) Behcet’s disease is associated with ulcers on the shins

ACKNOWLEDGEMENTS
We thank Melissa Praznovsky, Linda Roman, Flora Williams, and Tania Shulkin.

Authors’ affiliations
L B Trost, J K McDonnell, Department of Dermatology, Cleveland Clinic Foundation, USA

Funding: none.

Competing interests: none.

REFERENCES

Cutaneous manifestations of inflammatory bowel disease


ANSWERS
1. (A); 2. (C); 3. (D); 4. (D); 5. (B).
Important cutaneous manifestations of inflammatory bowel disease

L B Trost and J K McDonnell

doi: 10.1136/pgmj.2004.031633

Updated information and services can be found at:
http://pmj.bmj.com/content/81/959/580

References
This article cites 64 articles, 0 of which you can access for free at:
http://pmj.bmj.com/content/81/959/580#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/